Literature DB >> 8413869

Grade zero removal of supratentorial convexity meningiomas.

T Kinjo1, O al-Mefty, I Kanaan.   

Abstract

Although meningiomas are benign intracranial tumors, their frequency of recurrence after surgery has not been as low as expected. The recurrence rate of meningiomas is clearly related to the degree of tumor removal. Simpson Grade I removal, which entails excising the tumor and its dural and sinus attachments, is associated with the lowest rate of recurrence. To further minimize the recurrence of convexity meningiomas, we removed an additional dural margin of about 2 cm around the tumor (Grade 0 removal). For tumors involving bone, we removed the hyperostotic bone with a healthy margin and pericranium in en bloc resection. Between 1982 and 1992, 37 patients (15 men, 22 women) with an average age of 52.1 years were operated on by the above technique. Nineteen had a follow-up period of more than 5 years. To date, no tumors have recurred and no morbid incidences have occurred with this maneuver. We believe that the recurrence rate of convexity meningiomas can be diminished by including in the resection a margin of dura that might harbor a foci of tumor cells.

Entities:  

Mesh:

Year:  1993        PMID: 8413869     DOI: 10.1227/00006123-199309000-00007

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  20 in total

Review 1.  Contemporary surgical outcome for skull base meningiomas.

Authors:  Chien-Min Chen; Abel Po-Hao Huang; Lu-Ting Kuo; Yong-Kwang Tu
Journal:  Neurosurg Rev       Date:  2011-05-26       Impact factor: 3.042

2.  Uptake and tracer kinetics of O-(2-(18)F-fluoroethyl)-L-tyrosine in meningiomas: preliminary results.

Authors:  Jan F Cornelius; Gabriele Stoffels; Christian Filß; Norbert Galldiks; Philipp Slotty; Marcel Kamp; Mustafa el Khatib; Daniel Hänggi; Michael Sabel; Jörg Felsberg; Hans Jakob Steiger; Heinz H Coenen; Nadim J Shah; Karl-Josef Langen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-21       Impact factor: 9.236

3.  5-Aminolevulinic acid-induced protoporphyrin IX fluorescence in meningioma: qualitative and quantitative measurements in vivo.

Authors:  Pablo A Valdes; Kimon Bekelis; Brent T Harris; Brian C Wilson; Frederic Leblond; Anthony Kim; Nathan E Simmons; Kadir Erkmen; Keith D Paulsen; David W Roberts
Journal:  Neurosurgery       Date:  2014-03       Impact factor: 4.654

Review 4.  Opportunities for clinical research in meningioma.

Authors:  Michael A Vogelbaum; C Leland Rogers; Mark A Linskey; Minesh P Mehta
Journal:  J Neurooncol       Date:  2010-09-11       Impact factor: 4.130

5.  MMP-9 expression in meningiomas: a prognostic marker for recurrence risk?

Authors:  V Barresi; E Vitarelli; G Tuccari; G Barresi
Journal:  J Neurooncol       Date:  2010-07-21       Impact factor: 4.130

6.  Recurrence of Skull Base Meningiomas: The Role of Aggressive Removal in Surgical Treatment.

Authors:  Carlos Eduardo da Silva; Paulo Eduardo Peixoto de Freitas
Journal:  J Neurol Surg B Skull Base       Date:  2015-10-25

7.  Semaphorin3A immunohistochemical expression in human meningiomas: correlation with the microvessel density.

Authors:  Valeria Barresi; Enrica Vitarelli; Serenella Cerasoli
Journal:  Virchows Arch       Date:  2009-03-19       Impact factor: 4.064

Review 8.  Intracranial meningiomas of atypical (WHO grade II) histology.

Authors:  Leland Rogers; Mark Gilbert; Michael A Vogelbaum
Journal:  J Neurooncol       Date:  2010-08-26       Impact factor: 4.130

9.  Laser biospectroscopy and 5-ALA fluorescence navigation as a helpful tool in the meningioma resection.

Authors:  A A Potapov; S A Goryaynov; V A Okhlopkov; L V Shishkina; V B Loschenov; T A Savelieva; D A Golbin; A P Chumakova; M F Goldberg; M D Varyukhina; A Spallone
Journal:  Neurosurg Rev       Date:  2016-02-18       Impact factor: 3.042

10.  Recurrence and outcome in skull base meningiomas: do they differ from other intracranial meningiomas?

Authors:  Anil Nanda; Prasad Vannemreddy
Journal:  Skull Base       Date:  2008-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.